SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Kathleen Liddell · Study

Home/Author

Kathleen Liddell

10 works· latest 2022· 1 institutionscluster: provisionalORCID 0000-0003-2892-5008

h-index10

i1010

Citations270

Works here10

16

17

18

19

20

21

22

Most cited in this library

Patient data ownership: who owns your health?2021 · 69 citations
International transfers of health data between the EU and USA: a sector-specific approach for the USA to ensure an ‘adequate’ level of protection2020 · 60 citations
Standard contractual clauses for cross-border transfers of health data after Schrems II2021 · 29 citations
After Myriad, what makes a gene patent claim 'markedly different' from nature?2017 · 21 citations
Myriad's impact on gene patents2016 · 19 citations

Works

10 shown

European patent protection for medical uses of known products and drug repurposing

Nature Biotechnology·2022·4 authors·Open access

17citations

Mapping the European patent landscape for medical uses of known products

Nature Biotechnology·2021·4 authors·Open access

12citations

Patient data ownership: who owns your health?

Journal of Law and the Biosciences·2021·3 authors·Open access

69citations

Standard contractual clauses for cross-border transfers of health data after Schrems II

Journal of Law and the Biosciences·2021·3 authors·Open access

29citations

International transfers of health data between the EU and USA: a sector-specific approach for the USA to ensure an ‘adequate’ level of protection

Journal of Law and the Biosciences·2020·3 authors·Open access

60citations

Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine

Nature Biotechnology·2019·5 authors·Open access

16citations

Continental drift? Do European clinical genetic testing laboratories have a patent problem?

European Journal of Human Genetics·2019·8 authors·Open access

15citations

Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

Nature Biotechnology·2018·5 authors·Open access

12citations

After Myriad, what makes a gene patent claim 'markedly different' from nature?

Nature Biotechnology·2017·5 authors·Open access

21citations

Myriad's impact on gene patents

Nature Biotechnology·2016·4 authors

19citations